USRE49934EActiveUtility
Inhibitors of cellular metabolic processes
Est. expiryAug 31, 2036(~10.1 yrs left)· nominal 20-yr term from priority
C07D 487/04C07D 519/00C07F 9/6561A61P 35/00A61P 35/02A61P 43/00C07F 9/141A61K 31/519
77
PatentIndex Score
0
Cited by
158
References
45
Claims
Abstract
The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein R A , R B , R C , R D , and R E are defined herein.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A compound according to formula IA or a pharmaceutically acceptable salt thereof:
wherein
R A is selected from the group consisting of H, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 1 -C 6 -alkoxy, C 3 -C 14 -carbocycle, (C 3 -C 14 -carbocyclo)-C 1 -C 6 -alkyl-, 3- to 14-membered heterocycle or heterocyclo-C 1 -C 6 -alkyl- (wherein 1 to 4 heterocycle ring members are heteroatoms selected from N, O, and S), (3- to 14-membered heterocyclo)oxy-, C 6 -C 14 -aryl, (C 6 -C 14 -aryl)-C 1 -C 6 -alkyl-, C 6 -C 14 -aryloxy-, —(CH 2 ) 0-6 NR 1 (CH 2 ) 0-6 C(O)R 2 , NR 1 R 2 , C(O)NR 1 R 2 , NR 1 C(NR 2 )NR 1 R 2 , NR 1 C(NR 2 )(═NR 1 ), SR 1 , —CN, and —OH;
wherein each alkyl, alkenyl, alkoxy, aryl, and heterocycle is optionally substituted with one or more substituents selected from the group consisting of R, OR 1 , halo, —N═N—R 1 , NR 1 R 2 , —(C 1 -C 6 -alkyl)NR 1 R 2 , —C(O)OR 1 , —C(O)NR 1 R 2 , —OC(O)R 1 , —CN, —OP(O)(OR 1 ) 1-2 , and oxo;
R B is selected from the group consisting of H, C 2 -C 6 -alkenyl, and C 1 -C 6 -alkyl, wherein R B is optionally substituted by one or more R 1 ;
R C , R D , and R E are independently selected from the group consisting of C 3 -C 14 -carbocycle, C 6 -C 14 -aryl, and 3- to 14-membered heterocycle (wherein 1 to 4 heterocycle ring members are heteroatoms selected from N, O, and S),
wherein R C , R D , and R E are optionally substituted with one or more substituents selected from the group consisting of R 1 , —OR 1 , halo, —NR 1 R 2 , —(C 1 -C 6 -alkyl)-NR 1 R 2 , —C(O)OR 1 , —C(O)NR 1 R 2 , —NO 2 , —CN, and oxo; and
R 1 and R 2 are independently selected from the group consisting of H, D ( 2 H), —CN, —OH, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, NH 2 , —S(O) 0-2 —(C 1 -C 6 -alkyl), —S(O) 0-2 -(C 6 -C 14 -aryl), —C(O)(C 1 -C 6 -alkyl), —C(O)(C 3 -C 14 -carbocyclo), —C 3 -C 14 -carbocycle, C 6 -C 14 -aryl, 3- to 14-membered heterocycle or heterocyclo(C 1 -C 6 -alkyl)- (wherein 1 to 4 heterocycle ring members are heteroatoms selected from N, O, and S),
wherein each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocycle, and heterocycle moiety of R 1 and R 2 is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halo, —NH 2 , —NHC(O)(OC 1 -C 6 -alkyl), —NO 2 , —CN, oxo, —C(O)OH, —C(O)O(C 1 -C 6 -alkyl), —C 1 -C 6 -alkyl(C 1 -C 6 -alkoxy), —C(O)NH 2 , C 1 -C 6 -alkyl, —C(O)C 1 -C 6 -alkyl, —OC 1 -C 6 -alkyl, —Si(C 1 -C 6 -alkyl) 3 , C 6 -C 14 -aryl, —(C 1 -C 6 -alkyl)(C 6 -C 14 -aryl), 3- to 14-membered heterocycle or heterocyclo(C 1 -C 6 -alkyl)- (wherein 1 to 4 heterocycle ring members are heteroatoms selected from N, O, and S), and —O(C 6 -C 14 -aryl),
wherein each alkyl, aryl, and heterocyclo in R 1 and R 2 is optionally substituted with one or more substituents selected from the group consisting of hydroxy, —OC 1 -C 6 -alkyl, halo, —NH 2 , —(C 1 -C 6 -alkyl)NH 2 , —C(O)OH, CN, and oxo.
2. The compound according to claim 1 10, or a pharmaceutically acceptable salt thereof, wherein R D and R E are independently selected from C 3 -C 14 -carbocycle, C 6 -C 14 -aryl, and 3- to 14-membered heterocycle (wherein 1 to 4 heterocycle ring members are heteroatoms selected from N, O, and S) is C 5 -C 7 -carbocycle.
3. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein R D and R E are independently selected from C 3 -C 14 -carbocycle and C 6 -C 14 -aryl is C 6 -C 10 aryl.
4. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein R D and R E are independently selected from C 5 -C 7 -carbocycle and C 6 -C 10 -aryl.
5. The compound according to claim 4 10, or a pharmaceutically acceptable salt thereof, wherein R D and R E are independently selected from the group consisting of cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, and phenyl.
6. The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, wherein one of R D and R E is cyclohexyl or cyclohexenyl and the other is phenyl.
7. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R A is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 1 -C 6 -alkoxy, C 3 -C 14 -carbocycle, (C 3 -C 14 -carbocyclo)-C 1 -C 6 -alkyl-, 3- to 14-membered heterocycle or heterocyclo(C 1 -C 6 -alkyl)- (wherein 1 to 4 heterocycle ring members are heteroatoms selected from N, O, and S), C 6 -C 14 -aryl, (C 6 -C 14 -aryl)-C 1 -C 6 -alkyl-, C 6 -C 14 -aryloxy, —(CH 2 ) 0-6 NR 1 (CH 2 ) 0-6 C(O)R 2 , NR 1 R 2 , NR 1 C(NR 2 )NR 1 R 2 , —CN, and —OH.
8. The compound according to claim 7 , or a pharmaceutically acceptable salt thereof, wherein R A is selected from the group consisting of C 1 -C 6 -alkyl, —(CH 2 ) 0-6 )NR 1 (CH 2 ) 0-6 )C(O)R 2 , NR 1 R 2 , and NR 1 C(NR 2 )NR 1 R 2 .
9. The compound according to claim 8 , or a pharmaceutically acceptable salt thereof, wherein R A is C 1 -C 6 -alkyl or NR 1 R 2 .
10. The A compound according to claim 9 formula IA, or a pharmaceutically acceptable salt thereof,:
wherein:
R A is NR 1 R 2 ;
R B is selected from the group consisting of H, C 2 -C 6 -alkenyl, and C 1 -C 6 -alkyl, wherein R B is optionally substituted by one or more of R 1 ;
R C is selected from the group consisting of C 3 -C 14 -carbocycle, C 6 -C 14 -aryl, and 3- to 14-membered heterocycle (wherein 1 to 4 heterocycle ring members are heteroatoms selected from the group consisting of N, O, and S),
R D and R E are, independently, selected from the group consisting of C 5 -C 7 -carbocycle and C 6 -C 10 -aryl;
wherein R C , R D , and R E are optionally substituted with one or more substituents selected from the group consisting of R 1 , —OR 1 , halo, —NR 1 R 2 , —(C 1 -C 6 -alkyl)—NR 1 R 2 , —C(O)OR 1 , —C(O)NR 1 R 2 , —NO 2 , —CN, and oxo; and
R 1 and R 2 are independently selected from the group consisting of H, D ( 2 H), —CN, —OH, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, NH 2 , —S(O) 0-2 —(C 1 -C 6 -alkyl, —S(O) 0-2 —(C 6 -C 14 -aryl), —C(O)(C 1 -C 6 -alkyl, —C(O)(C 3 -C 14 -carbocyclo), —C 3 -C 14 -carbocycle, C 6 -C 14 -aryl, 3- to 14-membered heterocycle or heterocyclo(C 1 -C 6 -alkyl)- (wherein 1 to 4 heterocycle ring members are heteroatoms selected from the group consisting of N, O, and S),
wherein each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocycle, and heterocycle moiety of R 1 and R 2 is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halo, —NH 2 , —NHC(O)(OC 1 -C 6 -alkyl, —NO 2 , —CN, oxo, —C(O)OH, —C(O)O(C 1 -C 6 -alkyl), —C 1 -C 6 -alkyl(C 1 -C 6 -alkoxy), —C(O)NH 2 , C 1 -C 6 -alkyl, —C(O)C 1 -C 6 -alkyl, —OC 1 -C 6 -alkyl, —Si(C 1 -C 6 -alkyl) 3 , C 6 -C 14 -aryl, —(C 1 -C 6 -alkyl)(C 6 -C 14 -aryl), 3- to 14-membered heterocycle or heterocyclo(C 1 -C 6 -alkyl)- (wherein 1 to 4 heterocycle ring members are heteroatoms selected from the group consisting of N, O, and S), and —O(C 6 -C 14 -aryl),
wherein each alkyl, aryl, and heterocyclo in R 1 and R 2 is optionally substituted with one or more substituents selected from the group consisting of hydroxy, —OC 1 -C 6 -alkyl, halo, —NH 2 , —(C 1 -C 6 -alkyl)NH 2 , —C(O)OH, CN, and oxo.
11. The compound according to claim 10 , or a pharmaceutically acceptable salt thereof, wherein R 1 is H.
12. The A compoundaccording to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is one according to of formula IB:
wherein
R C is a C 3 -C 14 -carbocycle or a 3- to 14-membered heterocycle (wherein 1 to 4 heterocycle ring members are heteroatoms selected from the group consisting of N, O, and S),
each optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, —NH 2 , C 6 -C 14 -aryl, (C 6 -C 14 -aryl)-C 1 -C 6 -alkyl-, carboxy, —CN, oxo, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and —NH(C 1 -C 6 -alkyl), wherein the C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and NH(C 1 -C 6 -alkyl) are independently and optionally substituted with one or more of hydroxy, halogen, —NH 2 , carboxy, —CN, and or oxo;
R D and R E are independently a C 3 -C 14 -carbocycle or a 3- to 14-membered heterocycle (wherein 1 to 4 heterocycle ring members are heteroatoms selected from N, O, and S), each optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, —NH 2 , C 6 -C 14 -aryl, (C 6 -C 14 -aryl)-C 1 -C 6 -alkyl-, carboxy, —CN, oxo, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and —NH(C 1 -C 6 -alkyl), wherein the C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and NH(C 1 -C 6 -alkyl) are independently and optionally substituted with one or more of hydroxy, halogen, —NH 2 , carboxy, —CN, and oxo; and
R 1 is selected from the group consisting of H, C 1 -C 6 -alkyl, C 3 -C 14 -carbocycle, and 3- to 14-membered heterocycle (wherein 1 to 4 heterocycle ring members are heteroatoms selected from the group consisting of N, O, and S),
each optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, —NH 2 , —NO 2 , —CN, oxo, carboxy, —C(O)OC 1 -C 6 -alkyl, (C 1 -C 6 -alkyl)OC 1 -C 6 -alkyl-, —C(O)NH 2 , C 1 -C 6 -alkyl, —C(O)H, C 1 -C 6 -alkoxy, (C 1 -C 6 -alkyl)N(H)-aryl-, (C 6 -C 14 -aryl)C 1 -C 6 -alkyl-, 5- to 7-membered heteroaryl, (5- to 7-membered heteroaryl)-C 1 -C 6 -alkyl-, C 6 -C 14 -aryloxy, (C 6 -C 14 -aryl)(C 1 -C 6 -alkoxy)-, (5- to 7-membered heteroaryl)oxy-, and (5- to 7-membered heteroaryl)(C 1 -C 6 -alkoxy)-,
wherein the C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, (C 1 -C 6 -alkyl)N(H)—, —C(O)OC 1 -C 6 -alkyl, (C 1 -C 6 -alkyl)OC 1 -C 6 -alkyl-, —C(O)NH 2 , C 6 -C 14 -aryl, (C 6 -C 14 -aryl)C 1 -C 6 -alkyl-, 5- to 7-membered heteroaryl, (5- to 7-membered heteroaryl)-C 1 -C 6 -alkyl-, C 6 -C 14 -aryloxy, (C 6 -C 14 -aryl)(C 1 -C 6 -alkoxy)-, (5- to 7-membered heteroaryl)oxy-, and (5- to 7-membered heteroaryl)(C 1 -C 6 -alkoxy)-, are optionally substituted with one or more of hydroxy, halogen, —NH 2 , (C 1 -C 6 -alkyl)N(H)—, —COOH, —CN, and or oxo,
wherein each heteroaryl in R 1 has 1 to 4 heteroaryl ring members that are heteroatoms selected from the group consisting of N, O, and S.
13. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R D is C 3 -C 14 -carbocycle optionally substituted with one or more members of the group consisting of hydroxy, halogen, —NH 2 , —C(O)OH, —CN, oxo, alkyl, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)—,
wherein the C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)- are optionally substituted with one or more of hydroxy, halogen, —NH 2 , —C(O)OH, —CN, and or oxo.
14. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R D is phenyl.
15. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R D is cyclohex-1-en-1-yl.
16. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R E is C 3 -C 14 -carbocycle optionally substituted with one or more members of the group consisting of hydroxy, halogen, —NH 2 , —C(O)OH, —CN, oxo, alkyl, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)—,
wherein the C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)— are optionally substituted with one or more of hydroxy, halogen, —NH 2 , —C(O)OH, —CN, and or oxo.
17. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R E is selected from the group consisting of cyclohex-1-en-1-yl, ( 2 H 9 )cyclohex-1-en-1-yl, cyclohexan-1,3-dien-1-yl, 4,4-difluorocyclohex-1-en-1-yl, cyclopent-1-en-1yl, cyclopentyl, pyridin-3-yl, pyridin-2-yl, 4-methoxypyridin-3-yl, pyridin-2-yl, 1H-pyrazol-4-yl, 1H-pyrrol-3-yl, 4,4-difluoropiperidin-1-yl, 5,6-dihydro-2H-pyran-3-yl, 3,6-dihydro-2H-pyran-4-yl, 1H-pyrrol-3-yl, 1H-pyrrol-1-yl, tetrahydrofuran-3-yl, 3,3-difluoropyrrolidin-1-yl, and 3,6-dihydro-2H-pyran-4-yl.
18. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R E is phenyl.
19. The compound according to claim 18 , or a pharmaceutically acceptable salt thereof, wherein R D is cyclohex-1-en-1-yl.
20. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R C is C 3 -C 14 -carbocycle or 3- to 14-membered heterocycle (wherein 1 to 4 heterocycle ring members are heteroatoms selected from the group consisting of N, O, and S) and that is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, —NH 2 , —C(O)OH, —CN, oxo, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)—, wherein the C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)— are optionally substituted with hydroxy, halogen, —NH 2 , —C(O)OH, —CNand, or oxo.
21. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R C is selected from the group consisting of 4-hydroxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-trifluoromethoxyphenyl, 4-hydroxy-2-methylphenyl, 4-hydroxy-2-methoxyphenyl, 3,4-dihydroxyphenyl, 4-(2,2,2-trifluoroethoxy)phenyl, 4-(2-(dimethylamino)ethoxy)phenyl, 3-fluoro-4-hydroxyphenyl, 3-fluoro-4-methoxyphenyl, 2-chloro-4-hydroxyphenyl, 2-fluoro-4-methoxyphenyl, 3-amino-4-hydroxyphenyl, 3-amino-4-fluorophenyl, 3-(N,N-dimethylaminoethoxy)-4-hydroxyphenyl, 3-chloro-2-hydroxyphenyl, 3-hydroxyethoxy-4-hydroxyphenyl,
22. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R C is selected from the group consisting of 6-methoxypyridin-3-yl, 2-methoxypyridin-4-yl, 1H-pyrazol-4-yl, quinolin-6-yl, 2-methylquinolin-6-yl, 2-methoxyquinolin-6-yl, 2-hydroxymethylquinolin-6-yl, 3-hydroxy-2-methylquinolin-6-yl, 2-aminoquniazolin-6-yl, 4-aminoquinazolin-6-yl, cinnolin-6-yl, quinoxalin-6-yl, 2-chloroquinoxalin-6-yl, 3-chloroquinoxalin-6-yl, 3-aminoquinoxalin-6-yl, 3-hydroxyquinoxalin-6-yl, 3-methoxyquinoxalin-6-yl, 1,8-naphthyridin-3-yl, imidazo[1,2-a]pyridin-6-yl,
23. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R C is 4-methoxyphenyl.
24. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R 1 is a 3- to 14-membered heterocycle optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, —NH 2 , —NO 2 , —C(O)OH, —C(O)OC 1 -C 6 -alkyl, (C 1 -C 6 -alkyl)N(H)C(O)—, —CN, oxo, C 1 -C 6 -alkyl, —C(O)H, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)—,
wherein the C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and (C 1 -C 6 -alkyl)N(H)—, C(O)OC 1 -C 6 -alkyl, and (C 1 -C 6 -alkyl)N(H)C(O)— are optionally substituted with one or more of hydroxy, halogen, —NH 2 , (C 1 -C 6 -alkyl)N(H)—, —C(O)H, —CN, and or oxo.
25. The compound according claim 12 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of pyridin-2-yl, pyrazin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl, 1,3,5-triazin-2-yl, and 1,2,4-triazin-3-yl, each of which is optionally substituted with one or more of F, Cl, CN, OH, —NO 2 , —NH 2 , —NHMe, —C(O)NH 2 , and or methoxy.
26. The compound according claim 12 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of:
27. The compound according claim 12 , or a pharmaceutically acceptable salt thereof, wherein RI is selected from the group consisting of:
28. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
ring A and ring B are independently a carbocycle or a heterocycle each optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, amino, carboxy, CN, oxo, alkyl, alkoxy and alkylamino, wherein said alkyl, alkoxy and alkylamino are optionally substituted with hydroxy, halogen, amino, carboxy, CNand, or oxo;
ring C is a carbocycle or a heterocycle each optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, amino, carboxy, CN, oxo, alkyl, alkoxy and alkylamino, wherein said alkyl, alkoxy and alkylamino are optionally substituted with hydroxy, halogen, amino, carboxy, CN and or oxo; and
R 1 is H or alkyl, a carbocycle or a heterocycle each optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, amino, NO 2 , CN, oxo, carboxy, alkoxycarbonyl, alkoxyalkyl, aminocarbonyl, alkyl, acyl, alkoxy, alkylamino aryl, aralkyl, heteroaryl, heteroaralkyl, aryloxy, aralkoxy, heteroaryloxy and heteroaralkoxy, wherein said alkyl, alkoxy, alkylamino, alkoxycarbonyl, alkoxyalkyl, aminocarbonyl, aryl, aralkyl, heteroaryl, heteroaralkyl, aryloxy, aralkoxy, heteroaryloxy and heteroaralkoxy are optionally substituted with hydroxy, halogen, amino, alkylamino, carboxy, CN or oxo.
29. A compoundaccording to claim 1 , or a pharmaceutically acceptable salt thereof, that is selected from the following table group consisting of:
30. A compoundaccording to claim 1 , or a pharmaceutically acceptable salt thereof, that is selected from the following table group consisting of:
31. A method for inhibiting the synthesis of S-adenosyl methionine (SAM) from methionine and ATP by MAT2A in a cell, comprising introducing into the cell an effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 , 28 , 29 , and 30 claim 10.
32. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 , 28 , 29 , and 30 claim 10, and a pharmaceutically acceptable carrier.
33. A compound according to claim 10 that is
or a pharmaceutically acceptable salt thereof.
34. A compound according to claim 10 that is
or a pharmaceutically acceptable salt thereof.
35. A compound according to claim 10 that is
or a pharmaceutically acceptable salt thereof.
36. A compound according to claim 10 that is
or a pharmaceutically acceptable salt thereof.
37. A compound according to claim 10 that is
or a pharmaceutically acceptable salt thereof.
38. A compound according to claim 10 that is
or a pharmaceutically acceptable salt thereof.
39. A compound that is:
or a pharmaceutically acceptable salt thereof.
40. A method for inhibiting the synthesis of S-adenosyl methionine (SAM) from methionine and ATP by MAT2A in a cell, comprising introducing into the cell an effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 28.
41. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, of claim 28 and a pharmaceutically acceptable carrier.
42. A method for inhibiting the synthesis of S-adenosyl methionine (SAM) from methionine and ATP by MAT2A in a cell, comprising introducing into the cell an effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 29.
43. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, of claim 29 and a pharmaceutically acceptable carrier.
44. A method for inhibiting the synthesis of S-adenosyl methionine (SAM) from methionine and ATP by MAT2A in a cell, comprising introducing into the cell an effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 30.
45. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, of claim 30 and a pharmaceutically acceptable carrier.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.